Item Group
Inclusion and exclusion criteria
C1512693 (UMLS CUI [1,1])
C0680251 (UMLS CUI [1,2])
Elig.phs000760.v1.p1.1
Item
The seven healthy vaccine seroconverter subjects and seven healthy non-seroconverter subjects in the study were recruited at Duke University and were given TIV (Sanofi Pasteur, Swiftwater PA): 2007-2008 Fluzone® vaccine or 2008-2009 Fluzone® vaccine. Blood samples were collected prior to vaccination and on days seven and twenty-one after vaccination. Subject BFI-278 recruited at Stanford University was administered Influenza A (H1N1) 2009 monovalent inactivated vaccination in January 2010. Blood was collected immediately prior to vaccination and on days four to fourteen after vaccination. Ten months after receiving the monovalent H1N1 vaccine, BFI-278 was administered a seasonal trivalent inactivated vaccine that included the Influenza A/California/07/2009-like pandemic H1N1 antigenic component. Blood was drawn from BFI-278 prior to 2010 TIV vaccination, and at days seven and twenty-one post-vaccination.
boolean
C1512693 (UMLS CUI [1,1])
C0042196 (UMLS CUI [1,2])
C4042908 (UMLS CUI [1,3])
C1512693 (UMLS CUI [2,1])
C0042196 (UMLS CUI [2,2])
C1298908 (UMLS CUI [2,3])
C4042908 (UMLS CUI [2,4])
C1277698 (UMLS CUI [3,1])
C0011008 (UMLS CUI [3,2])
C0332152 (UMLS CUI [3,3])
C0042196 (UMLS CUI [3,4])
C3842672 (UMLS CUI [3,5])
C4082109 (UMLS CUI [3,6])
C0681850 (UMLS CUI [4,1])
C0242800 (UMLS CUI [4,2])
C0205394 (UMLS CUI [4,3])
C0019994 (UMLS CUI [4,4])
C1277698 (UMLS CUI [4,5])
C0011008 (UMLS CUI [4,6])
C0332152 (UMLS CUI [4,7])
C0042196 (UMLS CUI [4,8])
C3840892 (UMLS CUI [4,9])
C4082118 (UMLS CUI [4,10])
C0681850 (UMLS CUI [5,1])
C0242800 (UMLS CUI [5,2])
C0205394 (UMLS CUI [5,3])
C0019994 (UMLS CUI [5,4])
C1524062 (UMLS CUI [5,5])
C0042196 (UMLS CUI [5,6])
C1277698 (UMLS CUI [5,7])
C0011008 (UMLS CUI [5,8])
C0332152 (UMLS CUI [5,9])
C0042196 (UMLS CUI [5,10])
C3842672 (UMLS CUI [5,11])
C4082109 (UMLS CUI [5,12])